Is Enzolytics (ENZC) a Solid Buy After The Recent Correction?

Investors who are looking for stocks that might have recorded major gains over the past months could have a look at the Enzolytics Inc (OTCMKTS: ENZC) stock.

Although the stock corrected somewhat and went down by 35% from its peak recently, it is still up by as high as 2700% over the past two months. One of the most important things to keep in mind about Enzolytics is the fact that it owns the licensing rights to Pepsin Fraction peptide molecule. The molecule in question is meant for treating AIDS.

Related:  Fomo (ETFM) Gains Momentum On High Volume: Are You Excited?

However, that is not all. It is believed that the treatment is considerably different from other forms of treatment and does not have any toxicity problems. Last but not the least, the company claims that the treatment can also result in considerable cost savings and that is another attribute that might have influenced investors. The product has an addressable market that could be worth as huge as $37 billion by 2027.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.